Miller Anestesia

277. Heier T, Caldwell JE, Sessler DI, Miller RD: The

effect of local surface and central cooling on adduc-

tor pollicis twitch tension during nitrous oxide/

isoflurane and nitrous oxide/fentanyl anesthesia in

humans. Anesthesiology 72:807–811, 1990.

278. Miller RD,Agoston S, van der Pol F, et al: Hypother-

mia and the pharmacokinetics and pharmacodyna-

mics of pancuronium in the cat. J Pharmacol Exp

Ther 207:532–538, 1978.

279. Stenlake JB, Hughes R: In vitro degradation of atra-

curium in human plasma. Br J Anaesth 59:806–807,

1987.

280. Eriksson LI, Viby-Mogensen J, Lennmarken C: The

effect of peripheral hypothermia on a vecuronium-

induced neuromuscular block. Acta Anaesthesiol

Scand 35:387–392, 1991.

281. Thornberry EA, Mazumdar B: The effect of changes

in arm temperature on neuromuscular monitoring

in the presence of atracurium blockade.Anaesthesia

43:447–449, 1988.

282. Miller RD, Van Nyhis LS, Eger EI: The effect of

temperature on a

-tubocurarine neuromuscular

blockade and its antagonism by neostigmine. J

Pharmacol Exp Ther 195:237–241, 1975.

283. Miller RD, Roderick LL: Pancuronium-induced

neuromuscular blockade, and its antagonism by

neostigmine, at 29, 37 and 41°C. Anesthesiology

46:333–335, 1977.

284. Heier T, Clough D,Wright PM, et al: The influence

of mild hypothermia on the pharmacokinetics

and time course of action of neostigmine in anes-

thetized volunteers. Anesthesiology 97:90–95,

2002.

285. Sinatra RS, Philip BK, Naulty JS, Ostheimer GW:

Prolonged neuromuscular blockade with vecuro-

nium in a patient treated with magnesium sulfate.

Anesth Analg 64:1220–1222, 1985.

286. Fuchs-Buder T, Wilder-Smith OH, Borgeat A, Tas-

sonyi E: Interaction of magnesium sulphate with

vecuronium-induced neuromuscular block. Br J

Anaesth 74:405–409, 1995.

287. Tsai SK, Huang SW, Lee TY: Neuromuscular inte-

ractions between suxamethonium and magnesium

sulphate in the cat. Br J Anaesth 72:674–678, 1994.

288. Waud BE, Waud DR: Interaction of calcium and

potassium with neuromuscular blocking agents. Br

J Anaesth 52:863–866, 1980.

289. Al-Mohaya S, Naguib M, Abdelatif M, Farag H:

Abnormal responses to muscle relaxants in a patient

with primary hyperparathyroidism. Anesthesiology

65:554–556, 1986.

290. Price LH, Heninger GR: Lithium in the treatment

of mood disorders. N Engl J Med 331:591–598,

1994.

291. Abdel-Zaher AO: The myoneural effects of lithium

chloride on the nerve-muscle preparations of rats.

Role of adenosine triphosphate–sensitive potas-

sium channels. Pharmacol Res 41:163–178, 2000.

292. Hill GE,Wong KC, Hodges MR: Lithium carbonate

and neuromuscular blocking agents. Anesthesio-

logy 46:122–126, 1977.

293. Martin BA, Kramer PM: Clinical significance of the

interaction between lithium and a neuromuscular

blocker. Am J Psychiatry 139:1326–1328, 1982.

294. Usubiaga JE,Wikinski JA, Morales RL, Usubiaga LE:

Interaction of intravenously administered procaine,

lidocaine and succinylcholine in anesthetized sub-

jects. Anesth Analg 46:39–45, 1967.

295. Usubiaga JE, Standaert F: The effects of local anes-

thetics on motor nerve terminals. J Pharmacol Exp

Ther 159:353–361, 1968.

296. Kordas M: The effect of procaine on neuromuscular

transmission. J Physiol 209:689–699, 1970.

297. ThorpeWR, Seeman P: The site of action of caffeine

and procaine in skeletal muscle. J Pharmacol Exp

Ther 179:324–330, 1971.

298. Ozkul Y: Influence of calcium channel blocker

drugs in neuromuscular transmission. Clin Neuro-

physiol 118:2005–2008, 2007.

299. van Poorten JF, Dhasmana KM, Kuypers RS,

ErdmannW:Verapamil

and reversal of vecuronium

neuromuscular blockade.AnesthAnalg 63:155–157,

1984.

300. Baurain M, Barvais L, d’Hollander A, Hennart D:

Impairment of the antagonism of vecuronium-

induced paralysis and intra-operative disopyramide

administration. Anaesthesia 44:34–36, 1989.

301. Ornstein E,Matteo RS,Schwartz AE,et al: The effect

of phenytoin on the magnitude and duration of

neuromuscular block following atracurium or

vecuronium. Anesthesiology 67:191–196, 1987.

302. Spacek A, Neiger FX, Spiss CK, Kress HG: Chronic

carbamazepine therapy does not influence mivacu-

rium-induced neuromuscular block. Br J Anaesth

77:500–502, 1996.

303. Alloul K, Whalley DG, Shutway F, et al: Pharmaco

kinetic origin of carbamazepine-induced resistance

to vecuronium neuromuscular blockade in anesthe-

tized patients. Anesthesiology 84:330–339, 1996.

304. Kim CS,Arnold FJ, Itani MS, Martyn JA: Decreased

sensitivity to metocurine during long-term phen-

ytoin therapy may be attributable to protein binding

and acetylcholine receptor changes. Anesthesiology

77:500–506, 1992.

305. Melton AT, Antognini JF, Gronert GA: Prolonged

duration of succinylcholine in patients receiving

anticonvulsants: Evidence for mild up-regulation of

acetylcholine receptors? Can J Anaesth 40:939–942,

1993.

306. Miller RD, Sohn YJ, Matteo RS: Enhancement of

-tuborcurarine neuromuscular blockade by diure-

tics in man. Anesthesiology 45:442–445, 1976.

307. Scappaticci KA, Ham JA, Sohn YJ, et al: Effects of

furosemide on the neuromuscular junction. Anes-

thesiology 57:381–388, 1982.

308. Carmignani M, Scoppetta C, Ranelletti FO, Tonali

P: Adverse interaction between acetazolamide and

anticholinesterase drugs at the normal and myas-

thenic neuromuscular junction level. Int J Clin

Pharmacol Ther Toxicol 22:140–144, 1984.

309. Azar I, Cottrell J, Gupta B, Turndorf H: Furosemide

facilitates recovery of evoked twitch response after

pancuronium. Anesth Analg 59:55–57, 1980.

310. Hill GE, Wong KC, Shaw CL, Blatnick RA: Acute

and chronic changes in intra- and extracellular

potassium and responses to neuromuscular bloc-

king agents. Anesth Analg 57:417–421, 1978.

311. Glidden RS, Martyn JA, Tomera JF: Azathioprine

fails to alter the dose-response curve of

-tubocu-

rarine in rats. Anesthesiology 68:595–598, 1988.

312. Meyers EF: Partial recovery from pancuronium

neuromuscular blockade following hydrocortisone

administration. Anesthesiology 46:148–150, 1977.

313. Leeuwin RS, Veldsema-Currie RD, van Wilgenburg

H, Ottenhof M: Effects of corticosteroids on neuro-

muscular blocking actions of

-tubocurarine. Eur J

Pharmacol 69:165–173, 1981.

314. Parr SM, Robinson BJ, Rees D, Galletly DC: Interac-

tion between betamethasone and vecuronium. Br J

Anaesth 67:447–451, 1991.

315. Bouzat C,Barrantes FJ:Modulation of muscle nicotinic

acetylcholine receptors by the glucocorticoid hydro-

cortisone. Possible allosteric mechanism of channel

blockade. J Biol Chem 271:25835–25841, 1996.

316. Valera S, Ballivet M, Bertrand D: Progesterone

modulates a neuronal nicotinic acetylcholine recep-

tor. Proc Natl Acad Sci U S A 89:9949–9953, 1992.

317. Naguib M, Gyasi HK: Antiestrogenic drugs and

atracurium—a possible interaction? Can Anaesth

Soc J 33:682–683, 1986.

318. Ali HH, Wilson RS, Savarese JJ, Kitz RJ: The effect

of tubocurarine on indirectly elicited train-of-four

muscle response and respiratory measurements in

humans. Br J Anaesth 47:570–574, 1975.

319. Kopman AF, Yee PS, Neuman GG: Relationship of

the train-of-four fade ratio to clinical signs and

symptoms of residual paralysis in awake volunteers.

Anesthesiology 86:765–771, 1997.

320. Eriksson LI, Sundman E, Olsson R, et al: Functional

assessment of the pharynx at rest and during

swallowing in partially paralyzed humans: Simulta-

neous videomanometry and mechanomyography

of awake human volunteers. Anesthesiology

87:1035–1043, 1997.

321. Sundman E, Witt H, Olsson R, et al: The incidence

and mechanisms of pharyngeal and upper esopha-

geal dysfunction in partially paralyzed humans:

Pharyngeal videoradiography and simultaneous

manometry after atracurium. Anesthesiology

92:977–984, 2000.

322. Eriksson LI: Reduced hypoxic chemosensitivity in

partially paralysed man. A new property of muscle

relaxants? Acta Anaesthesiol Scand 40:520–523,

1996.

323. Eriksson LI: The effects of residual neuromuscular

blockade and volatile anesthetics on the control of

ventilation. Anesth Analg 89:243–251, 1999.

324. Igarashi A, Amagasa S, Horikawa H, Shirahata M:

Vecuronium directly inhibits hypoxic neurotrans-

mission of the rat carotid body. Anesth Analg

94:117–122, 2002.

325. Lien CA, Matteo RS, Ornstein E, et al: Distribution,

elimination, and action of vecuronium in the

elderly. Anesth Analg 73:39–42, 1991.

326. Caldwell JE: Reversal of residual neuromuscular

block with neostigmine at one to four hours after a

single intubating dose of vecuronium.AnesthAnalg

80:1168–1174, 1995.

327. Magorian TT, Lynam DP, Caldwell JE, Miller RD:

Can early administration of neostigmine, in single

or repeated doses, alter the course of neuromuscu-

lar recovery from a vecuronium-induced neuro-

muscular blockade? Anesthesiology 73:410–414,

1990.

328. Baurain MJ, d’Hollander AA, Melot C, et al: Effects

of residual concentrations of isoflurane on the

reversal of vecuronium-induced neuromuscular

blockade. Anesthesiology 74:474–478, 1991.

329. Soreq H, Seidman S: Acetylcholinesterase—new

roles for an old actor. Nat Rev Neurosci 2:294–302,

2001.

330. Silman I, Sussman JL, Acetylcholinesterase:: ‘classi-

cal’ and ‘non-classical’ functions and pharmacology.

Curr Opin Pharmacol 5:293–302, 2005.

331. Bevan DR, Donati F, Kopman AF: Reversal of neu-

romuscular blockade. Anesthesiology 77:785–805,

1992.

332. Beemer GH, Goonetilleke PH, Bjorksten AR: The

maximum depth of an atracurium neuromuscular

block antagonized by edrophonium to effect ade-

quate recovery. Anesthesiology 82:852–858, 1995.

333. Bevan JC, Collins L, Fowler C, et al: Early and late

reversal of rocuronium and vecuronium with neos-

tigmine in adults and children. Anesth Analg

89:333–339, 1999.

334. Kirkegaard H, Heier T, Caldwell JE: Efficacy of

tactile-guided reversal from cisatracurium-induced

neuromuscular block. Anesthesiology 96:45–50,

2002.

335. Caldwell JE, Robertson EN, Baird WL: Antagonism

of vecuronium and atracurium: Comparison of

neostigmine and edrophonium administered at 5%

twitch height recovery. Br J Anaesth 59:478–481,

1987.

336. Berg H, Roed J, Viby-Mogensen J, et al: Residual

neuromuscular block is a risk factor for postopera-

tive pulmonary complications. A prospective, ran-

domised, and blinded study of postoperative

pulmonary complications after atracurium, vecuro-

nium and pancuronium. Acta Anaesthesiol Scand

41:1095–1103, 1997.

337. Cronnelly R, Morris RB, Miller RD: Edrophonium:

Duration of action and atropine requirement in

humans during halothane anesthesia. Anesthesio-

logy 57:261–266, 1982.

338. Miller RD, Van Nyhuis LS, Eger EI 2nd, et al: Com-

parative times to peak effect and durations of action

674

Farmacología y anestesia